These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 28117615

  • 1. Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.
    Malerba M, Radaeli A, Montuschi P, Babu KS, Morjaria JB.
    Expert Opin Investig Drugs; 2017 Mar; 26(3):319-329. PubMed ID: 28117615
    [Abstract] [Full Text] [Related]

  • 2. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N.
    Int J Chron Obstruct Pulmon Dis; 2015 Mar; 10():1093-102. PubMed ID: 26089659
    [Abstract] [Full Text] [Related]

  • 3. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
    Monaco TJ, Hanania NA.
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):285-299. PubMed ID: 28868931
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Future of chronic obstructive pulmonary disease management.
    D'Urzo A, Vogelmeier C.
    Expert Rev Respir Med; 2012 Jun; 6(3):285-99. PubMed ID: 22788943
    [Abstract] [Full Text] [Related]

  • 7. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
    Dong YH, Chang CH, Gagne JJ, Hsu CL, Lai MS.
    Pharmacotherapy; 2016 Jan; 36(1):26-37. PubMed ID: 26799347
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.
    Malerba M, Radaeli A, Morjaria JB.
    Drug Discov Today; 2012 May; 17(9-10):496-504. PubMed ID: 22119310
    [Abstract] [Full Text] [Related]

  • 9. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P, Worsley S, Singh D, Román-Rodríguez M, Newby DE, Müllerová H.
    Int J Chron Obstruct Pulmon Dis; 2016 May; 11():2885-2895. PubMed ID: 27932872
    [Abstract] [Full Text] [Related]

  • 10. An update on LAMA/LABA combinations for COPD.
    Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA, Donohue JF.
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [Abstract] [Full Text] [Related]

  • 13. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M, Molimard M.
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [Abstract] [Full Text] [Related]

  • 14. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
    Rabe KF.
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):685-698. PubMed ID: 28443352
    [Abstract] [Full Text] [Related]

  • 15. A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD.
    Lal C, Strange C.
    Expert Opin Pharmacother; 2017 Dec; 18(17):1833-1843. PubMed ID: 29115881
    [Abstract] [Full Text] [Related]

  • 16. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle].
    Kume H.
    Nihon Rinsho; 2016 May; 74(5):813-9. PubMed ID: 27254952
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E, Montagni M, Riario-Sforza GG, Baroni M, Incorvaia C.
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [Abstract] [Full Text] [Related]

  • 18. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO, Young PM, Rogueda P, Lallement A, Iliev I, Traini D.
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [Abstract] [Full Text] [Related]

  • 19. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Aug; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 20. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.
    Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L.
    Expert Opin Drug Saf; 2018 Jun; 17(6):589-596. PubMed ID: 29716427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.